Fujian Province Tumor Hospital
9
2
2
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
22%
2 trials in Phase 3/4
100%
1 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer
Role: collaborator
A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma
Role: collaborator
A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease
Role: collaborator
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
Role: collaborator
A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
Role: collaborator
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
Role: collaborator
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
Role: collaborator
A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)
Role: collaborator
Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
Role: collaborator
All 9 trials loaded